David A. Siegel Pliant Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 455,200 shares of PLRX stock, worth $691,904. This represents 0.0% of its overall portfolio holdings.
Number of Shares
455,200
Previous 342,200
33.02%
Holding current value
$691,904
Previous $461,000
14.53%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding PLRX
# of Institutions
128Shares Held
57.7MCall Options Held
245KPut Options Held
86.7K-
Tang Capital Management LLC San Diego, CA6MShares$9.12 Million0.42% of portfolio
-
Black Rock Inc. New York, NY4.97MShares$7.56 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.95MShares$6 Million0.16% of portfolio
-
Morgan Stanley New York, NY3.75MShares$5.71 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.01MShares$4.58 Million25.76% of portfolio
About PLIANT THERAPEUTICS, INC.
- Ticker PLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,682,000
- Market Cap $74M
- Description
- Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...